Home›Insulin Glargine-Yfgn

Insulin Glargine-Yfgn

Also known as: Semglee

Insulin Analog

Route: Subcutaneous

Check Insulin Glargine-Yfgn Interactions →

39 interactions on record

Insulin Glargine-Yfgn has 39 known drug interactions based on U.S. FDA drug labeling data. 13 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acidifying Agents, Angiotensin Ii, Disopyramide. Patients taking Insulin Glargine-Yfgn should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 39
Major: 13
Moderate: 24

Major (13)

Insulin Glargine-Yfgn + Acidifying Agents— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Angiotensin Ii— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Disopyramide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Fibrates— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Fluoxetine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Liraglutide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Macrolide Antibiotics— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Mao Inhibitors— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Monoamine Oxidase Inhibitors (Maois)— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Octreotide— Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be re…
Insulin Glargine-Yfgn + Pentoxifylline— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Pramlintide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Salicylates— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Moderate (24)

Insulin Glargine-Yfgn + Albuterol— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Yfgn + Alcohol— May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be requir…
Insulin Glargine-Yfgn + Clonidine— May increase or decrease blood glucose lowering effect and may blunt hypoglycemia signs/symptoms. Dosage adjustment and …
Insulin Glargine-Yfgn + Clozapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitorin…
Insulin Glargine-Yfgn + Corticosteroids— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Danazol— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Diuretics— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Epinephrine— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Yfgn + Estrogens— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Glucagon— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Guanethidine— May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Isoniazid— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Lithium— May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be requir…
Insulin Glargine-Yfgn + Niacin— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Nonselective Beta-Adrenergic Antagonists— May increase or decrease blood glucose lowering effect and may blunt hypoglycemia signs/symptoms. Dosage adjustment and …
Insulin Glargine-Yfgn + Olanzapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitorin…
Insulin Glargine-Yfgn + Oral Contraceptives— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Pentamidine— May cause hypoglycemia followed by hyperglycemia. Dosage adjustment and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Phenothiazines— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Protease Inhibitors— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Reserpine— May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Somatropin— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Yfgn + Terbutaline— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Yfgn + Thyroid Hormones— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Acidifying Agents⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Angiotensin Ii⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Disopyramide⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Fibrates⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Fluoxetine⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Liraglutide⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Macrolide Antibiotics⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Mao Inhibitors⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Monoamine Oxidase Inhibitors (Maois)⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Octreotide⚠️Major

Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Pentoxifylline⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Pramlintide⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Salicylates⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Albuterol🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Alcohol🟡Moderate

May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Clonidine🟡Moderate

May increase or decrease blood glucose lowering effect and may blunt hypoglycemia signs/symptoms. Dosage adjustment and increased glucose monitoring required.

Insulin Glargine-Yfgn + Clozapine🟡Moderate

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Corticosteroids🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Danazol🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Diuretics🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Epinephrine🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Estrogens🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Glucagon🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Guanethidine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Isoniazid🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Lithium🟡Moderate

May increase or decrease blood glucose lowering effect. Dosage adjustment and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Niacin🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Nonselective Beta-Adrenergic Antagonists🟡Moderate

May increase or decrease blood glucose lowering effect and may blunt hypoglycemia signs/symptoms. Dosage adjustment and increased glucose monitoring required.

Insulin Glargine-Yfgn + Olanzapine🟡Moderate

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Oral Contraceptives🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Pentamidine🟡Moderate

May cause hypoglycemia followed by hyperglycemia. Dosage adjustment and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Phenothiazines🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Protease Inhibitors🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Reserpine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Somatropin🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Terbutaline🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Thyroid Hormones🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Yfgn + Acetazolamideℹ️Unknown

Table 8: Clinically Significant Drug Interactions with Insulin Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.

Insulin Glargine-Yfgn + Somatostatinℹ️Unknown

Table 8: Clinically Significant Drug Interactions with Insulin Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.